Member Info for Hurst10

The U.S. is planning to beef up testing requirements for international travelers entering the country in the light of the new omicron variant of the coronavirus that causes COVID-19, including shortening the time a test must be taken prior to travel

With ref to AVA6000 and US trials, it is only a matter of when, not if,a triple A pharma company signs up and as mentioned before Astra Zeneca down the road in Cambridge, who is already working with several of the companies Avacta is involved with, AZN will no doubt make sure Avacta remains a U.K. and Cambridge player.AVA6000 -AZN-Avacta !!!
Look at the trouble we have with ARM holdings!!

BEGO now 124-34, best bid, US buyers joining us.

Agree, it is a $74 bill market, the majors will be knocking on the door, to sign up JV’s , upfront payments and milestone payments being lined up.
The AVA6000 is now ahead of schedule and with the FDA giving green light for phase 1 US trials, plenty of media coverage will be heading Avacta’s direction.

Fantastic news, now commencing phase 1 US trials.
Will get significant press coverage in the US.

Now patient in Belgium, Europe will be closing down, no Air travel from Africa etc.
South African patient was a HIV patient.
Do not forget Avacta produce an effective vaccine against ZIKA, which is now spreading in India

EU name it,a “ Variant of concern “

In summary, the AffiDX(R) SARS-CoV-2 Lateral Flow Rapid Antigen Test has excellent analytical sensitivity (LOD) of 50 pg/ml S1 spike protein, which appears sensitive enough to detect the lowest viral loads of relevance to the Intended Use Case, with a read time of 20 minutes. As far the Group is aware, this is the most sensitive S1 spike lateral flow test available.
From the above one should conclude that :
As Avacta could detect the Delta Variant,so the company is in good position to work with the new variant.
They can sell their test in SA.

Yep, sure more to come this afternoon I am sure

A new variant of COVID-19 identified in Botswana with dozens of mutations is being watched closely, amid fears it could be resistant to the effect of currently-used vaccines.

The B.1.1.529 variant has more mutations affecting the spike protein targeted by vaccines than any other strain identified to date, although it’s not yet clear if it is more or less transmissible.

There have only been a few confirmed cases so far, including three in Botswana, six in South Africa where surveillance is more robust, and one in Hong Kong in an individual who travelled from South Africa before being tested.

The mutations in the spike protein has been described as “really awful” by Tom Pea****, a virologist at Imperial College’s department of infectious disease, in a tweet.

WHO met on Thursday to discuss new coronavirus variant circulating in South Africa and Botswana.Called B.1.1529 carrying an unusually large number of mutations.

WSJ: “COVID-19 antibody-tests in demand, as people worry about immunity” ?
We have the new German chancellor going flat out with compulsory vaccination and Sweden’s new PM wants the same!

Europe heading for full lockdown and judging from local press in Scandinavia and Germany, compulsory testing at Schools about to be a daily event, Thermo Fisher out shopping for LFT Covid test manufacturer, Novartis long $20bill post Roche stake disposal looking for Radiotherapy JV’s…however right now TESTING is required and among schools on a daily basis!

It is Friday and we have the self tests registered with it?s own brand name, Medusa19 safely back from Germany, Abingdon talking of ? significant orders from Avacta ?,short covering from Jupiter,one would be a fool not to stir things up and see what one can get at the opening, before the Yanks arrives.

We are back having Berenberg on best bid and worst offer, guess who they are buying for !!!

Novartis having sold their stake in Roche and got $21bill and will have much more if they dispose of their Sandoz generic unit, have shareholders demanding action from the company to go shopping. The company is also involved in Radiotherapy and buying, as discussed before, we will have M&A activity stepping up a gear or two in the sector and Avacta is about to attract a lot of attention on all fronts, so again we could see more JV’s, with huge upfront payments.

More Infectious Covid Delta Sub-Variant Spreading Fast in U.K., Survey Shows https://www.bloomberg.com/news/articles/2021-11-18/covid-delta-sub-variant-is-spreading-fast-in-u-k-survey-shows

The next couple of weeks will give Avacta tremendous share price momentum, press coverage and overseas business en masse!
At current price with upcoming news flow and business, it looks very cheap, but we all know that.
130-5 by close of business today and then we have Friday off course and Medusa back in town, CE approval and Avacta will ship OTC self tests.
Manufacturing capacity will double with another partner announced and soon there will be an Avacta Rapid LFT test hanging on every tree in Europe.

Sorry if it is a repeat.
“
From ABDX RNS :
We have received significant purchase orders for manufacturing batches from Vatic and Avacta, in advance of completion of technical transfer of their products, and we are putting in place the required component stock to allow us to seamlessly move into manufacturing in due course. The transfer of these antigen tests is timely given the move towards private-sector testing in the UK, the transition to cost-effective lateral flow testing from PCR testing for travel as well as the increased focus on antigen testing starting to emerge in the United States.“

Wrong post, meant for a different stock.
We will be above 125 at the opening.
COVID and testing mayhem in mainland Europe